Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | FABP6 | P51161 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065081 | 0.89 | KDM4E (0.51) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL11277575 | 0.87 | NPSR1 (0.72) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL16134552 | 0.78 | ABL1 (0.69) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL3499235 | 0.78 | ABL1 (1.00) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL12909208 | 0.78 | ALDH1A1 (1.00) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL14642947 | 0.78 | ABL1 (0.69) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL29575638 | 0.78 | ABL1 (1.00) | ABL1ALDH1A1POLBHPGDRAB9A | |
| SCHEMBL24329791 | 0.78 | ALDH1A1 (0.60) | ABL1ALDH1A1SMN1; SMN2HTTABCC4 | |
| SCHEMBL30469417 | 0.78 | ALDH1A1 (0.60) | ABL1ALDH1A1SMN1; SMN2HTTABCC4 | |
| SCHEMBL2243148 | 0.77 | CHEK2 (0.80) | ABL1ALDH1A1POLBHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0301422-A2 | Thiomethyl and sulfinylmethyl derivatives having gastric acid antisecretory activity, processes for the preparation thereof and pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.p.A. (IT) | 1989-02-01 | — | — | EP | claimed |
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| CN-1457339-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-19 | — | — | CN | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
| US-5066652-A | ANTIULCER AGENTS | CHIESI FARMACEUTICI S.P.A. (IT) | 1991-11-19 | — | — | US | disclosed |
| EP-0301422-A2 | Thiomethyl and sulfinylmethyl derivatives having gastric acid antisecretory activity, processes for the preparation thereof and pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.p.A. (IT) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | ABL1 2316/4885ALDH1A1 1755/4885POLB 2246/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | ABL1 1553/4885ALDH1A1 2001/4885POLB 2113/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | ABL1 2316/4885ALDH1A1 1755/4885POLB 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.